Lumida
/CERS
⌘K
Cerus Corp

Cerus Corp

CERS
$3.13USD↓-2.49%-0.08 today

MARKET CAP

627.2M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$3 – $3

52W RANGE

$1
$3

AI Summary

Stalk
StalkMedium

CERS remains in a Stage 2 advancing uptrend, preserving higher highs above the rising 50 DMA. However, recent rejection at the 9 and 21 EMAs and a short-term downtrend suggest timing is unfavorable now. A pullback toward the rising EMAs or the 50 DMA support region would present a higher-probability entry opportunity.

  • ↑Product revenue +24% YoY to $53.7M; full-year guidance lifted to $227–231M
  • ↑Agreement with Blood Centers of America expands reach to half of U.S. supply
  • ↓Gross margin fell to 52% from 58.8% YoY, squeezing profit margins
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Cerus Corporation (NASDAQ: CERS) is a leading biotechnology company focused on blood safety technologies, primarily through its INTERCEPT Blood System. The company aims to enhance the safety and availability of transfusions by inactivating pathogens in blood components, thereby positioning itself as a key player in transforming global blood safety standards. With a robust focus on innovative solutions, Cerus is strategically positioned within the healthcare and biopharmaceutical sectors to address critical transfusion challenges while navigating a highly regulated marketplace.

Bull says

  • ↑Product revenue +24% YoY to $53.7M; full-year guidance lifted to $227–231M
  • ↑Agreement with Blood Centers of America expands reach to half of U.S. supply
  • ↑Q1 non-GAAP EBITDA positive at $4M, eighth straight profitable quarter
  • ↑Operating expenses down 7% YoY; cash balance of $80.4M supports runway
  • ↑Preparing FDA submission for I&T 100 device to broaden product line
  • ↑High liquidity and rising demand for INTERCEPT trials indicate strong momentum

Bear says

  • ↓Gross margin fell to 52% from 58.8% YoY, squeezing profit margins
  • ↓Profitability remains weak; government-funded contracts expose timing risk
  • ↓Elevated earnings yield and leverage risk point to valuation vulnerabilities
  • ↓Stock volatility is high, deterring conservative investors
  • ↓Geopolitical logistics challenges may delay international shipments
  • ↓Regulatory and competitive hurdles could slow new product launches

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 05-22-2026bullish

Transcript signals

Bull points

  • For the first quarter of 2025, we reported product revenue of $43.2 million, a 13 percent increase and at the midpoint of the 10 to 15 percent guidance we provided in January. Higher North American platelet sales, along with increasing U.S. demand for IFC, were the principal drivers of growth this quarter.
  • First quarter North American product revenues increased 22 percent compared to the same period from the prior year.
  • Looking ahead to the balance of this year, based on the robust first quarter performance, coupled with the growing demand for both our platelet and IFC product lines, we are reiterating our full year 2025 product revenue guidance range of 194 to $200 million, which includes expected IFC revenue contribution of $12 to $15 million.

Bear points

  • Operating expenses for the first quarter totaled $36.9 million compared to $34.3 million for Q1 of 2024. This increase reflects the elevated activities driving government contract revenue, advancement of our LED illumination device globally, and cost of living adjustments for our employee base.
  • The year-over-year increase in SG&A expenses reflect modestly higher employee-related expenses, which we had also anticipated.
Read full transcript analysis ›